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a b s t r a c t
COPD is the second most common cause of pulmonary hypertension, and is a common complication of
severe COPD with signiﬁcant implications for both quality of life and mortality. However, the use of a
rigid diagnostic threshold of a mean pulmonary arterial pressure (mPAP) of 25mHg when considering
the impact of the pulmonary vasculature on symptoms and disease is misleading. Even minimal exertion
causes oxygen desaturation and elevations in mPAP, with right ventricular hypertrophy and dilatation
present in patients with mild to moderate COPD with pressures below the threshold for diagnosis of
pulmonary hypertension. This has signiﬁcant implications, with right ventricular dysfunction associated
with poorer exercise capability and increased mortality independent of pulmonary function tests.
The compliance of the pulmonary artery (PA) is a key component in decoupling the right ventricle
from the pulmonary bed, allowing the right ventricle to work at maximum efﬁciency and protecting the
microcirculation from large pressure gradients. PA stiffness increases with the severity of COPD, and
correlates well with the presence of exercise induced pulmonary hypertension. A curvilinear relationship
exists between PA distensibility and mPAP and pulmonary vascular resistance (PVR) with marked loss of
distensibility before a rapid rise in mPAP and PVR occurs with resultant right ventricular failure. This
combination of features suggests PA stiffness as a promising biomarker for early detection of pulmonary
vascular disease, and to play a role in right ventricular failure in COPD. Early detection would open this
up as a potential therapeutic target before end stage arterial remodelling occurs.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
COPD is the second most common cause of pulmonary hyper-
tension after left sided heart disease [1]. Pulmonary hypertension
(Cor Pulmonalewhen associatedwith right heart failure in COPD) is
relatively common in severe COPD and is present in >50% of pa-
tients awaiting lung transplantation [2]. The incidence increases
with increasing severity of COPD, with pulmonary hypertension
present in 5% of moderate (GOLD stage II), 27% of severe (GOLD
stage III) and 53% of very severe (GOLD stage IV) COPD [3]. The true
incidence in mild to moderate COPD however is poorly appreciated
due to the absence of large scale epidemiological studies [4]. In
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comparison to other causes of pulmonary hypertension the pul-
monary pressure elevations are modest, however survival is poor
and correlates better with the pulmonary pressures and pulmonary
vascular resistance than with the severity of airﬂow obstruction
[5e8].
Pulmonary hypertension is deﬁned as a mean pulmonary arte-
rial pressure (mPAP) greater than or equal to 25 mmHg at rest [9].
However: Pulmonary vascular changes occur in mild COPD before
pulmonary hypertension occurs [10]; Right ventricular dysfunction
has been observed in normoxaemic COPD patients with normal
pulmonary arterial pressures [11]; and right ventricular hypertro-
phy is one of the earliest cardiac changes and is present even in
mild COPD [12e14]. Additionally in both mice and guinea pig
models, vascular remodelling occurs even before the onset of
emphysema [15e17]. The notion of an elevated rest pressure as a
cut-off is also restrictive in evaluating the role of the pulmonary
arteries and right heart as even minimal exertion causes marked
elevations in mPAP and oxygen desaturation in COPD, with exercise
induced pulmonary hypertension present in 35%e58% of patients
with normoxaemia or mild hypoxia [5,18e20].
Therefore the pulmonary hypertension model, whereby right
ventricular failure occurs once pulmonary hypertension exists, is a
misnomer, and an alternate should be considered - the right
ventriculo-arterial model.
1.1. Vascular changes
Vascular remodelling within COPD develops secondary to
intimal hyperplasia, withmuscularisation of the arterioles andwith
rather little change in the tunica media [21,22]. This hyperplasia is
induced by proliferation of smooth muscle cells and the deposition
of elastic and collagen ﬁbres [23,24]. Originally hypoxia was held to
be the driving force behind this remodelling, however similar
arterial changes are present in smokers with and without COPD,
and arterial changes can be observed inmild COPDwhen hypoxia is
yet to develop [10,23,25]. The vascular remodelling in COPD is most
likely due to endothelial dysfunction and apoptosis which in turn
causes remodelling, capillary loss and small vessel thrombosis [26].
This is likely due to a combination of local inﬂammatory mediators
released from the endothelial dysfunction in the adjacent pulmo-
nary parenchyma, and direct effects from the inhaled cigarette
smoke on the vascular endothelium [24,26]. However an experi-
mental study by Ferrer et al. in guinea pig models shows hypoxia
still plays a contributory role, as a hypoxic environment after
cigarette exposure induced signiﬁcantly greater changes in pul-
monary arterial pressures and pulmonary vascular remodelling
than cigarette smoking or hypoxia alone [17]. More recently the
pulmonary vascular sympathetic nerves which control the pul-
mopulmonary baroreceptor reﬂex originating at the pulmonary
trunk has been proposed to be of signiﬁcant importance in the
development of pulmonary arterial hypertension [27]. This is evi-
denced by a rise in pulmonary arterial pressures and pulmonary
vascular resistance (PVR) induced by stretching the branch pul-
monary arteries [27e30]. In a single study by Chen et al. [31] on 21
patients with signiﬁcant pulmonary hypertension despite
maximum medical therapy, intravascular pulmonary artery
denervation with cessation of medical therapy resulted in signiﬁ-
cant improvement in pulmonary pressures and exercise capacity.
However the role of this reﬂex in humans is still controversial and
has also yet to be evaluated in COPD induced pulmonary hyper-
tension [32].
1.1.1. The right ventriculo-arterial model
1.1.1.1. Right ventricle. The right ventricle (RV) got off to an inaus-
picious start in the 1940s and 50s when a series of papers showed
no signiﬁcant alterations in the pulmonary arterial or systemic
pressures following open ablation of the right heart in a dog model,
leading one of the authors to conclude that “a normal, contractile
right ventricular wall is not necessary for the maintenance of a
normal circulation” [33e35]. Despite this apparent swan song for a
signiﬁcant role of the right ventricle, a paper in 1982 demonstrated
that the open pericardial model did not accurately represent the
functional haemodynamics of the heart [36]. Goldstein et al.
demonstrated that when the right coronary artery was infarcted
within an intact pericardium there was a profound and rapid fall in
left ventricular pressures due to a fall in left ventricular (LV) pre-
load, equalisation of RV and LV pressures and elevated intra-
pericardial pressures which did not occur when they repeated their
experiment after pericardiectomy. Thus there is a marked ventric-
ular interdependence due to the shared pericardial compartment,
shared interventricular septum and the dependence of the left
heart preload on the output of the right [37e43].
Recent work has shown the importance of the right heart in
health and disease. In health the right ventricle responds to exer-
cise, obesity and traditional cardiovascular risk factors in a manner
similar to, but independent of, the left ventricle [44e46]. A
decreased RV mass is associated with an increased risk of devel-
oping dyspnoea, and an increased RV mass is associated with an
increased risk of future congestive cardiac failure and cardiovas-
cular mortality in a healthy population [47,48]. In patients with
COPD, right ventricular remodelling is apparent even early in the
disease with right ventricular hypertrophy and diastolic dysfunc-
tion present in mild and moderate COPD with systolic impairment
occurring in severe COPD [12,13]. This has signiﬁcant implications
with right ventricular dysfunction associated with poorer exercise
capabilities and increased mortality independent of pulmonary
function tests [49,50].
1.1.1.2. Pulmonary artery. There has been a great deal of recent
interest in systemic arterial stiffening in COPD due to the mecha-
nistically plausible link this provides between COPD and the excess
cardiovascular mortality associated with this condition [51]. In
comparison to the systemic arterial circulation there are several key
differences in the nature of the vascular tree between that of the
pulmonary and systemic circulation. The pulmonary artery is a low
pressure, high distensibility system which acts to transform the
highly pulsatile right ventricular output into the near steady ﬂow at
the capillary level [52]. The distal pulmonary vascular bed is also
comprised of highly distensible vessels that, through distension
and recruitment of themicrovascular bed, are able to accommodate
large increases in volume such as during exercise. This response is
the opposite of that experienced in the systemic circulation where
exercise induces vasoconstriction in the majority of the vascular
tree other than the vessels supplying the muscles. This inbuilt
reserve means that resting pulmonary arterial pressures will only
rise relatively late in a disease process when 60e70% of the bed is
obstructed [53]. The peripheral distensability of the vessels also
differs from the systemic circulation where only the proximal ar-
teries act as capacitance vessels, expanding and contracting with
each beat of the heart, while the peripheral vessels are responsible
for resistance. Due to the dual function of the vessels, there is an
inverse relationship between the resistance and capacitance of the
pulmonary circulation, with the product of the two (the resistance-
compliance time constant) remains the same in both health and
disease [54].
The pulmonary arteries and microcirculation have distinct ef-
fects on the right ventricular afterload which can be split into two
key components e the steady component required to drive and
maintain forward ﬂow and the oscillatory component required to
overcome the pulsatile component of ﬂow. The steady component
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is a function of peripheral vascular resistance whereas the oscilla-
tory component is a function both proximal and distal pulmonary
arterial stiffness [55]. Even in the healthy adult, 30% of the right
ventricular output is spent on generating pulsations (compared
with only 10% in the systemic circulation) [56]. This energy is
considered wasted in terms of ventricular power output, but is
crucial in acting as a blood reservoir and maintaining steady ﬂow
through the pulmonary tree [57]. As the pulmonary artery stiffens
the oscillatory component of the workload increases, although re-
mains as a constant of the total energy expenditure of the right
ventricle [58,59]. As the artery stiffens it also starts to dilate and
become less compliant, and the dilation of this in relation to the
aorta has been shown to be a useful clinical marker in COPD, with a
PA:aortic ratio>1 an independent predictor of future acute exac-
erbations, exercise capacity, pulmonary hypertension andmortality
[60e63].
The compliance of the pulmonary artery is a key component in
decoupling the right ventricle from the pulmonary bed, allowing
the right ventricle to work at maximum efﬁciency and protecting
the microcirculation from large pressure gradients [52,64]. Indeed
the stiffness of the pulmonary artery is a strong determinant of
right ventricular function [65], and increased stiffness causes distal
pulmonary arterial endothelial dysfunction and inﬂammation
[66,67]. Increased stiffness is independently associated with
reduced functional capacity [68], and higher mortality than the
pulmonary artery pressures or pulmonary vascular resistance
[69e73]. While vascular distensability is partly dependant on un-
derlying distending pressures [74,75], multiple studies have shown
the intrinsic stiffness of the arterial walls to be increased in pul-
monary hypertension independently of these [76e80].
1.1.1.3. Right ventriculo-arterial model. Optimal ventriculo-arterial
coupling occurs when there is maximal transference of potential
energy from one elastic chamber to another, e.g. from the ventricle
to the artery. This is dependent on the elastance e the change in
pressure for a given change in volume e of the two chambers [81].
The ventricular elastance (EES) is a load independentmeasure of the
ventricular contractility combined with the modulating effects of
the geometric and structural properties of the ventricle [82]. It
relies on measuring the response of the ventricular pressure to
increasing volumes (see Fig. 1). The arterial elastance (EA) is an
index incorporating the elements affecting arterial load including
pulmonary vascular resistance, arterial compliance, characteristic
impedance, and systolic and diastolic time interval [83,84]. The EA/
EES calculates the extent of ventriculo-arterial coupling.
At rest the ventricle and pulmonary artery are coupled so that
the right ventricle is working at optimal efﬁciency which occurs
when the stroke work is maximal with minimal oxygen con-
sumption [55,85e87]. This has been shown to occur when EA is half
EES [87e89]. In exercise this moves towards optimal coupling when
there is maximal cardiac efﬁciency which is where there is
maximum ﬂow generation with minimal energy loss (EA ¼ EES)
[90e92]. Interestingly the optimal values for energy efﬁciency and
cardiac efﬁciency are similar throughout a variety of studied
mammals suggesting it has been conserved throughout mamma-
lian evolution [93,94]. During exercise, arterial stiffness has a pro-
gressively and intensity-dependant greater impact on EA than PVR
with the result that EA increases on exercise despite a fall in PVR in a
manner paralleling the rise in arterial stiffness [95e97]. A similar
relationship is present in pulmonary hypertension whereby pul-
monary stiffness has a 1.2e18 fold greater contribution to right
ventricular workload than PVR [74,76,54]. In the systemic circula-
tion, age and hypertension (two known factors associated with
increased arterial stiffness) result in an exaggerated increase in EA
during exercise increasing the pulsatile load on the heart and in
turn decreasing left ventricular efﬁciency [90,98]. This exaggerated
response secondary to arterial stiffening may explain the rapid rise
in mPAP observed in COPD during exercise despite a stable or
minimal rise in PVR [18]. Indeed in a study by Hilde et al., an in-
crease in pulmonary arterial stiffness was observed during exercise
with a greater contribution from this to changes in mPAP than PVR
[3]. Further indirect evidence comes from a study by Kubo et al.
which showed the pulmonary arterial wall thickness to be related
to exercise pulmonary pressures rather than resting pulmonary
pressures, and to correlate highly with change in pressure from rest
to exercise [99].
When the EA increases so that the EA:EES is consistently above
0.5 the ventricle adapts to the increased workload by inducing
hypertrophy [101]. This increases the EES thereby returning the
ventriculo-arterial system to its most energy efﬁcient state, albeit at
a slightly higher energy consumption than previously [102e104].
As EA continues to rise the right ventricle eventually fails to adapt
with a resultant decrease in the EES and thereby a rapid increase in
EA/EES indicating uncoupling and reduced myocardial efﬁciency
[87,105].
Fourie et al. demonstrated that myocardial efﬁciency reached a
maximumwhen the EA reached 1mmHgml1 (corresponding to an
mPAP of 20 mmHg), while maximum stroke work corresponded to
an EA of 2 mmHgml1 (corresponding to a MPAP of 30e40 mmHg)
[52]. This corresponds with observations that at approximately
40 mmHg the pulmonary artery reaches it maximum dimension
and minimal distensability [78,105,106]. Consistent with this, Ste-
vens et al. demonstrated that in patients with pulmonary hyper-
tension there was a curvilinear relationship between RV function
and PA distensibility with marked loss of pulmonary artery
distensibility without commensurate loss of ventricular function
until only minimal distensibility remained when a rapid decom-
pensation of the right ventricle occurred [76]. A similar curvilinear
relationship has also been observed in COPD between pulmonary
arterial stiffness and peripheral vascular resistance, with a rapid
rise in PVR only occurring after signiﬁcant stiffening of the pul-
monary arteries has occurred [11]. Pulmonary stiffness is increased
early in pulmonary hypertension development, and is increased
even in those with exercise induced pulmonary hypertension, both
in mixed pulmonary arterial hypertension studies and in COPD
[3,11,78,106]. This combination of features suggest pulmonary
Fig. 1. Calculation of EA:EES in the right ventricle and pulmonary artery. Ventricular
end systolic pressure-volume is linear and characterised by the slope Ees and is
generated by measuring pressure-volume loops under gradated preload and afterload
conditions. Reproduced from Wang et al., 2011 [100]. Ea ¼ Arterial elastance;
Ees ¼ Ventricular elastance.
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arterial stiffness as a promising biomarker for detection of early
disease and as a potential therapeutic target before end stage
arterial remodelling occurs with dire consequences for the right
ventricle.
1.1.2. Measuring pulmonary artery stiffness
The stiffness of the pulmonary artery can be quantiﬁed using a
variety of metrics, with these measuring stiffness locally, regionally
or systemically. Table 1 summarises the various methods of
measuring arterial stiffness and the commonmethods for acquiring
these. As can be seen from the table the majority of these require
knowledge of the arterial pressures to calculate the stiffness. In the
arterial circulation this is not a signiﬁcant issue as the brachial
arterial pressures are readily obtained with a sphygmomanometer,
as mean BP and diastolic BP are relatively constant throughout the
large arteries [107]. However in the pulmonary arteries this pro-
vides a signiﬁcant hurdle as an external measurement of the
pressures is not readily available. Despite numerous attempts to
quantify pulmonary arterial pressures and vascular resistance using
echocardiography, CT and MRI, none of these have yet proven ac-
curate enough to negate the need for invasive measurement with
right heart catheterisation [108e115].
1.1.2.1. Right heart catheterisation. Right heart catheterisation can
be used to calculate several metrics of arterial stiffness, including
capacitance, PWV and elastance, although the latter two require
dedicated catheters and equipment not routinely available in the
catheter laboratory. In addition, it can be combinedwith techniques
for the visualisation of the pulmonary artery cross sectional area
such as MRI or intravascular ultrasound, to derive a wide range of
metrics of arterial stiffness and ventriculo-arterial coupling. Table 2
summarises the studies looking at invasive assessment of pulmo-
nary arterial stiffness. Despite its utility, RHC has numerous disin-
centives including its invasive nature, cost, and exposure to ionising
radiation. While the combination of MRI and right heart catheter-
isation allows catheter guidance without exposure to ionising ra-
diation and simultaneous acquisition of anatomical and pressure
measurements, it does not negate the invasive or costly nature of
Table 1
Measures of arterial stiffness e Calculations, deﬁnitions and alternate means of assessment.
Calculation Deﬁnition Method of assessment
Local
Pulsatility (%) (maxA e minA)/minA X 100 Relative change in lumen area during the cardiac cycle MRI Echocardiography IVUS
Compliance (mm2/mmHg) (maxA e minA)/PP Absolute change in lumen area for a given change in pressure RHC plus MRI/Echo/IVUS
Distensibility (%/mmHg) [(maxA e minA)/PP X minA] X 100 Relative change in lumen area for a given change in pressure RHC plus MRI/Echo/IVUS
Elastic modulus (mmHg) PP X minA/(maxA e minA) Pressure change driving a relative increase in lumen area RHC plus MRI/Echo/IVUS
Stiffness index (N/A) Ln(sPAP/dPAP)/[(maxA e minA)/minA] Slope of the function between distending arterial
pressure and arterial distension
RHC plus MRI/Echo/IVUS
Young's elastic modulus [3(1 þ minA/WCSA)]/Distensibility Wall thickness for a given distensibility RHC plus IVUS
Regional
Capacitance (mm3/mmHg) SV/PP Change in volume associated with a given change in pressure RHC
PWV (ms1) Dd/Dt (TT technique) DQ/DA
(Flow-area technique)
Speed of transmission of pressure wave RHC MRI
Systemic
Elastance (mmHgml1) EA/EES ¼ (ESP/SV)/(ESP/ESV-V0) Change in pressure for a given change in volume RHC with ﬂow-volume loops
A ¼ area; d ¼ distance; dPAP ¼ diastolic pulmonary artery pressure; EA ¼ Arterial elastance; Echo ¼ echocardiography; EES ¼ Ventricular elastance; IVUS ¼ intravascular
ultrasound; maxA ¼ maximum cross sectional area; mina ¼ minimum cross sectional area; MRI ¼ magnetic resonance imaging; PP ¼ pulse pressure; PWV ¼ pulse wave
velocity; Q¼ Flow over a single heart beat; RHC¼ right heart catheter; sPAP¼ systolic pulmonary artery pressure; SV¼ stroke volume; t¼ time; WCSA¼Wall cross sectional
area.
Table 2
Summary of studies looking at invasive measurement of pulmonary arterial stiffness.
Study Population No Method Finding
Milnor et al. [118] Mixed PH 7 RHC Increased impedance in PH
Nakayama et al. [119] Mixed PH 62 RHC Increased augmentation index and earlier inﬂection time in PH
Castelain et al. [77] Mixed PH 14 RHC Increased augmentation index and earlier inﬂection time in PH
Mahapatra et al. [70] Mixed PH 104 RHC Capacitance strongest predictor of mortality in PH. On multivariate analysis, capacitance
was the only statistically signiﬁcant predictor of mortality.
Hilde et al. [11] a COPD 98 RHC PA compliance greatly reduced in COPD Gold 2,3 and 4
Hilde at al [3] a COPD 98 RHC PA compliance fell with exercise in patients with and without PH, with similar elevations
in mPAP during exercise between the two groups.
Muthurangu et al. [120] IPAH 17 RHC with MRI Inverse relationship between compliance and PVRI and mPAP. A fall in compliance was
evident in 7/17 following nitric oxide inhalation
Kuehne et al. [87] Mixed 12 RHC with MRI Increased elastance in PH, with resultant ventriculo-arterial uncoupling
Kopec et al. [121] IPAH 26 RHC with IVUS PWV high in IPAH (mean PWV 10 ms1) with excellent correlation with compliance
(b ¼ 0.81) and reasonable correlation with mPAP (b ¼ 0.48)
Lau et al., 2012 [79] IPAH 8 RHC with IVUS Increase in all measure of pulmonary arterial stiffness. Inverse curvilinear relationship
between mPAP and compliance and distensibility. No change in PA stiffness following
6 months of bosentan therapy.
Rodes-Cabau et al. [72] IPAH 20 RHC with IVUS Reduced pulsatility in PH, with reduced pulsatility predictive of future mortality.
Epoprostenol infusion increased pulsatility by 53%.
Lau et al., 2014 [122] IPAH 5 RHC with IVUS High PWV in IPAH (mean PWV 10.6 ms1) with the reﬂected backward compression
wave carrying 31% of the energy of the forward compression wave
COPD ¼ chronic obstructive pulmonary disease; CoV¼ Coefﬁcient of variation; EIPH ¼ Exercise induced pulmonary hypertension; FEV1 ¼ Forced expiratory volume in 1 s;
HV¼Healthy volunteers; IPAH¼ Idiopathic pulmonary arterial hypertension; NYHA¼New York heart association; PASP¼ Pulmonary artery systolic pressure; PH¼ Pul-
monary hypertension; PWV ¼ pulse wave velocity; QA ¼ ﬂow by area; TT ¼ transition time; 6MWT ¼ 6 min walking test.
a Drawn from the same population.
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the study [116,117]. Of the measures of arterial stiffness, only pul-
satility and pulse wave velocity can be derived entirely non-
invasively.
1.1.2.2. Pulsatility. Multiple studies have shown reduced pulsatility
in pulmonary hypertension, [68,69,80,106,123e125]. A single
echocardiography study has shown reduced pulmonary artery
pulsatility in COPD, which correlated with right ventricular func-
tional parameters [126]. A single abstract using cardiac MR has also
described decreasing pulsatility with increasing severity of COPD
[127] (Table 3). However, as discussed above, the pulmonary stiff-
ness is dependant not only upon distending pressures, but also
upon the intrinsic elasticity of the pulmonary vessel wall, thus a fall
in pulmonary pulsatility does not differentiate a fall in pulsatility
due to a fall in stroke volume or in distending pressures from that of
a rise in arterial stiffness.
1.1.2.3. Pulse wave velocity. Pulse wave velocity (PWV) is the speed
at which the pressurewave, generated by ventricular contraction, is
transmitted through the arterial tree. This is directly related to
vessel wall elasticity, with increased stiffness leading to increased
PWV [128]. A reﬂected pressure wave is present which is generated
when the pressure wave is reﬂected from the termination of the
arteries, with alterations in the smallest arteries increasing the size
of the reﬂected wave while large artery stiffening increases the
PWV [118]. In health this reﬂected wave only represents a tiny
fraction of the total output energy, and arrives in diastole and re-
duces preload of the subsequent ventricular contraction
[92,118,129,130]. However in pulmonary hypertension this can
reach 30% of the forward wave energy. with an increased PWV
resulting in the earlier arrival of the reﬂected wave during systole
thereby increasing the afterload of the heart and thus cardiac
workload [77,119,122,131e133].
PWV is an establishedmarker of arterial stiffness in the systemic
circulation with aortic pulse wave velocity shown to be associated
with future cardiovascular events, and to improve risk stratiﬁcation
[134]. Transcutaneous waveform analysis methods are the gold
standard for aortic PWV measurement including pressure [135],
distension [136], and ﬂow waveform [137]. However a trans-
cutaneous approach is not possible for the pulmonary arteries.
While PWV can be measured invasively on right heart catheter-
isation [118], magnetic resonance imaging is a possible alternative
for non-invasive assessment of the pulmonary arteries using ﬂow
waveforms [138]. It is performed by the acquisition of ECG gated
phase contrast sequences which measure ﬂow the in proximal
main pulmonary artery and in the mid right or left pulmonary ar-
teries. A distance can be calculated between the two imaging
planes (Fig. 2), and the pulse wave timed from when it leaves the
main pulmonary artery until it arrives in branch pulmonary arteries
thus allowing a speed between the two points to be generated
[138]. MRI derived pulse wave velocity has been previously vali-
dated against both invasive and non-invasive techniques in the
aorta [139e141]. Several studies have shown this to be a feasible
and reproducible technique in the pulmonary arteries in healthy
volunteers [138,142], with the observed pulse wave velocity of
1.96e2.3 ms1 similar to that obtained invasively [118,129]. Pulse
wave velocity is raised in pulmonary hypertension on both invasive
andMRI assessment (See Table 2) [121,143]. To date there have been
no studies assessing pulmonary PWV in COPD.
1.1.3. Pulmonary arterial stiffness as a treatment target
Traditional treatments of pulmonary hypertension such as
phosphodiesterase inhibitors and endothelin-1 receptor antago-
nists have yielded disappointing results despite their success in
treating pulmonary hypertension, primarily due to worsening
ventilatory-perfusion mismatches [144e148]. However these
treatments have all focussed on altering the peripheral vasculature.
Table 3
Summary of studies looking at non-invasive measurement of pulmonary arterial stiffness.
Study Population No Method Finding
Pulsatility
Bogren et al. [159] b Mixed PH 4 MRI Pulsatility 23% in HV and 8% in PH
Paz et al. [160] HV 9 MRI No difference in pulsatility between the main pulmonary artery, right pulmonary artery and
left pulmonary arteries.
Gan et al. [69] Suspected PH 70 MRI Right pulmonary artery pulsatility showed a curvilinear relationship with mortality. Pulsatility <16%
Jardim et al. [125] b IPAH 19 MRI <10% pulsatility predicts non-responders to acute vasodilator testing with 100% sens and 56% spec.
Sanz et al. [124] a Suspected PH 59 MRI Pulsatility 41% in non-PH and 17.4% in PH. No difference in pulsatility between different causes of PH.
Sanz et al. [78] a Suspected PH 94 MRI No difference in pulsatility between group without PH and EIPH. Pulsatility <40% predicted
PH with 93% sens. and 63% spec.
Kang et al. [68] Mixed PH 35 MRI Pulsatility correlated with 6MWT (R2 ¼ 0.61, p < 0.001)<20% pulsatility predicted poor function
(6MWT <400m) with 82% sens. and 94% spec.
Stevens et al. [76] a Suspected PH 124 MRI Pulsatility correlates with right ventricular function
Stevens et al. [161] Suspected PH 43 MRI Pulsatility correlated with exercise capacity while RHC pressures did not.
Swift et al. [106] Suspected PH 134 MRI Pulsatility elevated even in very mild elevations in PVR. Pulsatility predicted mortality.
Revel et al. [162] b Suspected PH 45 CT Pulsatility of 16.5% predicted PH with sens 86% and spec 96%.
Pasierski et al. [80] Suspected PH 19 Echo Pulsatility reduced in pulmonary hypertension with a linear relationship between pulsatility and PASP
Mahapatra et al. [71] Suspected PH 54 Echo Capacitance was the strongest predictor of mortality including invasive pressure measurements
Ertan et al. [126] COPD 54 Echo Right pulmonary artery pulsatility reduced in COPD patients, with signiﬁcant differences between
NYHA functional classes.
Liu et al. [127] COPD 135 MRI Pulsatility falls with increasing severity of COPD, with a positive association with %predicted FEV1
and inversely correlated with %emphysema
PWV
Peng et al. [142] HV 17 MRI PWV 1.96 ± 0.27 with high intra-scan and inter-scan reproducibility (5.5% and 10.9% respectively)
Bradlow et al. [138] HV 10 MRI No signiﬁcant difference in PWV using the left or right pulmonary arteries. CoV 12% for both intra
and inter-observer assessment.
Ibrahim et al. [143] Heterogeneous 33 MRI PWV raised in pulmonary hypertension. Comparable measurements between TT and QA methods.
COPD ¼ chronic obstructive pulmonary disease; CoV¼ Coefﬁcient of variation; EIPH ¼ Exercise induced pulmonary hypertension; FEV1 ¼ Forced expiratory volume in 1 s;
HV¼Healthy volunteers; IPAH¼ Idiopathic pulmonary arterial hypertension; NYHA¼New York heart association; PASP¼ Pulmonary artery systolic pressure; PH¼ Pul-
monary hypertension; PWV ¼ pulse wave velocity; QA ¼ ﬂow by area; TT ¼ transition time; 6MWT ¼ 6 min walking test.
a Drawn from the same population.
b Different calculation for % pulsatility so not directly comparable to other studies.
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Given the greater impact of pulmonary stiffness on remodelling,
drugs to target and ameliorate this process may be a novel route to
target. Due to the relatively recent identiﬁcation of the importance
of pulmonary arterial stiffness in right ventricular remodelling,
there have been relatively few studies targeted at its treatment.
Despite this there are several studies suggestive of promising av-
enues for further exploration.
Statins have been proposed as a route to reduce systemic arterial
stiffness [149], although a meta-analysis showed mixed response
with two studies showing improvement, one showing no change
and another showing progression of stiffening [150]. Statins in
guinea pigs andmice with emphysema have been shown to reverse
arterial remodelling and halt the formation of emphysema
[151,152]. Indirect evidence of the beneﬁts from statins in COPD
related pulmonary hypertension come from observational studies
showing lower pulmonary arterial pressures in patients on statins
prior to right heart catheterisation [153]. Furthermore a study on
pulmonary arterial stiffness showed that other than mPAP, the only
other factors independently associated with pulmonary arterial
stiffness was LDL cholesterol and BMI [121]. Statins are also asso-
ciated with increased exercise capacity and reduced mortality in
COPD [154e156], however due to the observational nature of these
studies the underpinning mechanisms are still in debate [157,158].
Xanthine oxidase inhibitors have been shown to improve
endothelial function and arterial stiffness in the systemic circula-
tion [163e167]. They have also been shown to reduce endothelial
dysfunction induced by smoking and obstructive sleep apnoea
[168e170] e a condition similar to COPD in its effects of intermit-
tent hypoxia [171]. Additionally allopurinol inhibits hypoxia
induced pulmonary vasoconstriction, pulmonary hypertension,
endothelial dysfunction and vascular remodelling in hypoxic ani-
mal models of pulmonary hypertension [172e176]. It has been
shown to reduce airway reactive nitrogen species production in
COPD, however its effects on smoking induced pulmonary vascular
damage has not been assessed [177].
As with xanthine oxidase inhibitors, mineralocorticoid receptor
antagonists have been shown to improve systemic endothelial
function and arterial stiffness [178e180]. In 2 separate mouse
models of pulmonary hypertension, mineralocorticoid receptor
antagonists prevented or reversed adverse pulmonary vascular
remodelling with improved pulmonary vascular resistance, pul-
monary artery pressure, and remodelling of the right ventricle
[181]. A group in Bethesda, USA are currently recruiting patients
with pulmonary hypertension without right heart failure to eval-
uate its efﬁcacy in humans in modulating pulmonary vascular
remodelling [182]. Its use in COPD has not currently been assessed.
Long term oxygen therapy improves survival in severe COPD
and reduces pulmonary arterial pressures and vascular resistance
while improving cardiac output [6,183]. It has also been shown to
reduce peripheral arterial stiffness in COPD, however its effects on
the pulmonary arterial stiffness has not been evaluated [184].
There are also several new classes of pharmaceutical agents
currently being designed which speciﬁcally target the processes
causing arterial stiffening. Currently these are all being targeted at
systemic vascular remodelling and are in the pre-clinical stages,
however should they prove successful at preventing or reversing
systemic arterial remodelling they would be promising agents for
evaluation in pulmonary remodelling. The most promising of these
are TGF-B1 antagonists, and drugs targeting the advanced glycation
end products (AGEs) [185]. TGF-B1 is responsible for extracellular
matrix remodelling and vascular ﬁbrosis in chronic inﬂammatory
conditions, whilst AGE form irreversible cross-links with collagen
and elastin, reducing the elasticity of the arterial wall [185].
2. Conclusions
Pulmonary arterial stiffness holds a crucial role in right ven-
tricular dysfunction in pulmonary hypertension, and demonstrates
promise as a useful biomarker in the development of this disease.
Early work shows similar promise in COPD, and further work is
warranted to explore this promising new area.
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